GSK/XenoPort file sNDA for Horizant in PHN
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has filed a supplemental new drug application (sNDA) in the US requesting approval of XenoPort's Horizant (gabapentin enacarbil) extended-release tablets for the management of postherpetic neuralgia (PHN) in adults.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.